

## Remuneration report

### 1. Introduction

Gentian Diagnostics ASA ("the Company") and its subsidiaries (together "the Group") develops and manufactures high-quality, in vitro diagnostic reagents. Gentian's expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and heart failures. This 2024 Remuneration Report ("Remuneration Report") has been prepared in accordance with the requirements of the Norwegian Code of Practice for Corporate Governance 2024 and the Public Companies Act §6-16aog 6-16b.

The main principle of Gentian Diagnostics' remuneration policy for the executive management group is that the company should not be a wage leader, but the executive management shall be offered a competitive salary. The compensation arrangements shall be easy to manage and understand, long-term and possess flexibility. The total compensation arrangement should be linked to the company's earnings and performance, and to the individual elements of the personal terms.

The board determines remuneration for the CEO, while the CEO determines remuneration for the management group. Compensation of the executive management is based on market terms and evaluated on a yearly basis.

The executive management remuneration consists of a fixed salary and a variable part linked to the company's achievement. The criteria are reviewed annually and are linked to internal goals and budgets. In addition, the executive management is included in the Group's share option programme. Total remuneration in 2024 was in line with the criteria set for total compensation in 2024.

The executive management is included in the same pension plan as other employees to the extent applicable. Other benefits are of minor financial importance such as free access to communication tools for the management team to be available and compensation for the use of private car for business related travel. The CEO has the right to six month's salary in case the contract is terminated by the company. No other executives have any rights to receive additional compensation when leaving the company.

The board believes that the remuneration policy has been applied as presented and approved by the annual general meeting in 2024 and that it has contributed to retain, motivate and preserve the relevant experience of the executive management. The board also believes that the application of the remuneration policy has stimulated to a culture for remuneration that promotes the Company's business strategy and long-term interests and sustainability.

The remuneration to the executive management has promoted the achievement of results and leadership in accordance with the Company's values and reflect the performance of the individual executive. Considerations have also been given to increase and growth over time in the remuneration and the considerations have formed a part of the board's assessment whether the remuneration to the executive management has been reasonable.

### 2. Total compensation

In the below table 1 and 2 for total compensation, bonus is achieved bonus for 2023 paid in 2024 and bonus achieved in 2022 paid in 2023.

Table 1 – Salary and other remunerations to management in 2024 (NOK 1 000):								
		Wages and salaries	Bonus	Pension costs	Share based payments	Other remuneration	Proportion of remuneration	
							Fixed	Variable
Matti Heinonen <sup>1)</sup>	Chief Executive Officer	1 196	-	-	12	162	99 %	1 %
Hilja Ibert <sup>2)</sup>	Chief Executive Officer	1 370	633	-	979	57	47 %	53 %
Njaal Kind <sup>3)</sup>	Group Chief Financial Officer	2 470	339	77	457	9	76 %	24 %
Aleksandra Havelka	Chief Scientific Officer	1 509	231	410	235	43	81 %	19 %
Markus Jaquemar	Chief Commercial Officer	2 440	418	-	341	-	76 %	24 %
Frank Frantzen <sup>4)</sup>	Chief Technology Officer	712	-	39	8	19	99 %	1 %
Total compensation to management		9 698	1 621	526	2 032	290		

1) CEO from 1 October 2024

2) CEO until 29 April 2024, wages and salaries includes board remuneration from 1 May 2024

3) Acting CEO from 30 April to 30 September 2024

4) CTO from 5 August 2024

**Table 2 - Salary and other remunerations to management in 2023 (NOK 1 000):**

		Wages and salaries	Bonus	Pension costs	Share based payments	Other remuneration	Proportion of remuneration	
							Fixed	Variable
Hilja Ibert	Chief Executive Officer	3 141	449	-	624	158	75 %	25 %
Njaal Kind	Group Chief Financial Officer	2 161	220	67	584	9	74 %	26 %
Aleksandra Havelka	Chief Scientific Officer	1 270	93	344	191	3	85 %	15 %
Markus Jaquemar	Chief Commercial Officer	2 360	247	-	226	-	83 %	17 %
Total compensation to management		8 932	1 008	411	1 625	170		

Matti Heinonen, Hilja Ibert and Markus Jaquemar receives their compensation in Euro. Aleksandra Havelka receives her compensation in SEK. Share based payments are in NOK.

**Table 3 - Accrued bonus to management recognised in the 2024 accounts (NOK 1 000):**

		Bonus
Matti Heinonen *	Chief Executive Officer	97
Njaal Kind	Group Chief Financial Officer	293
Aleksandra Havelka	Chief Scientific Officer	206
Markus Jaquemar	Chief Commercial Officer	328
Frank Frantzen *	Chief Technology Officer	103
<b>Total</b>		<b>1 027</b>

\* Pro-rata bonus.

**Table 4 - Remuneration to the Board and Nomination Committee in 2024 (NOK 1 000):**

		Board	Nomination Committee
Hilja Ibert <sup>1)</sup>	Chairperson	233	-
Thomas Settevik <sup>2)</sup>	Chairperson	100	-
Espen T. Jørgensen	Board member	167	-
Kari E. Krogstad	Board member	167	-
Fredrik Thoresen	Board member	167	-
Monika Neuman <sup>2)</sup>	Board member	50	-
Kjersti Grimsrud	Board member	167	-
Andreas Berdal	Chairperson Nomination Committee	-	30
Haakon Sæter	Board member Nomination Committee	-	15
Runar Vatne	Board member Nomination Committee	-	15
Erling Sundrehagen <sup>3)</sup>	Board member Nomination Committee	-	15
<b>Total compensation to the Board and Nomination Committee</b>		<b>1 050</b>	<b>75</b>

1) Was appointed Chairperson in May 2024

2) Left the Board in May 2024

3) Passed away 9 October 2024

**Table 5 - Remuneration to the Board and Nomination Committee in 2023 (NOK 1 000):**

		Board	Nomination Committee
Thomas Settevik	Chairperson	300	-
Espen T. Jørgensen	Board member	150	-
Kari E. Krogstad	Board member	150	-
Fredrik Thoresen	Board member	150	-
Monika Neuman	Board member	150	-
Frank Frantzen <sup>3)</sup>	Board member	150	-
Kjersti Grimsrud <sup>1)</sup>	Board member	100	-
Susanne Stuffers <sup>2)</sup>	Board member	50	-
Thomas Kramar <sup>2)</sup>	Board member	50	-
Andreas Berdal	Chairperson Nomination Committee	-	30
Haakon Sæter	Board member Nomination Committee	-	15
Runar Vatne	Board member Nomination Committee	-	15
Erling Sundrehagen	Board member Nomination Committee	-	15
<b>Total compensation to the Board and Nomination Committee</b>		<b>1 250</b>	<b>75</b>

1) Was appointed Board member in May 2023

2) Left the Board in May 2023

3) Left the Board in December 2023

### 3. Short-term incentive programme – bonus arrangements

The short-term incentive programme is defined to incentivise the individual executive for their performance. The executive management are members of the company's bonus program where performance is evaluated, and bonus potentially awarded once per year. Bonus payment is only triggered if the group achieves approved targets pertaining to sales growth. In addition to the aforementioned financial target which defines the maximum pay-out (if any) each individual member of the bonus programme is measured against a set of individual performance criteria. Annual bonuses shall amount to maximum 40% of base salary. The tables below specify the performance achievement for the executive management in 2024 and the maximum bonus for each member of the executive management in 2024 and 2025.

Per 2024	Performance Criteria	Weight	Performance	
			Achieved	% of target
Company objectives	Financial goals	30 %	13 %	44 %
	Non-financial goals	70 %	31 %	44 %

	Target bonus in per cent of base salary	
	2024	2025
Matti Heinonen	10 %	40 %
Njaal Kind	30 %	30 %
Aleksandra Havelka	30 %	30 %
Markus Jaquemar	30 %	30 %
Frank Frantzen	16 %	30 %

#### 4. Share based compensation - option programme to management

In 2018, the company launched a share option programme for the executive management and key personnel. Under the share option programme, options may be allocated to the executive management and key personnel. The options entitle the option holder to purchase a defined number of shares to a pre-defined value after a specific period. The company may decide settlement in cash. Settlement in shares is conditional upon an autorisation from the general meeting for a share issue. The board determines the detailed criteria of the share option programme and related agreements.

Annual allocation of options is to be resolved by the board of the company in order to maximise the effect of the allocation(s). Currently, the total number of outstanding options cannot exceed 10.0% of the outstanding shares of the company. The options shall have a pre-defined strike price which can be adjusted for dividends and other relevant share capital ratios.

The following option allocations have been awarded to the executive management:

Table – 8

<b>Matti Heinonen</b>	<b>2024</b>	<b>2023</b>
Outstanding options 01.01	-	-
Options granted	100 000	-
Options forfeited	-	-
Options exercised	-	-
Options expired	-	-
Outstanding options 31.12	100 000	-

<b>Hilja Ibert</b>	<b>2024</b>	<b>2023</b>
Outstanding options 01.01	359 924	359 925
Options granted	-	139 962
Options forfeited	-	-
Options exercised	-	-
Options expired	-139 962	-139 963
Outstanding options 31.12	219 962	359 924

<b>Njaal Kind</b>	<b>2024</b>	<b>2023</b>
Outstanding options 01.01	180 670	175 661
Options granted	40 000	40 000
Options forfeited	-	-
Options exercised	-	-
Options expired	-40 000	-34 991
Outstanding options 31.12	180 670	180 670

<b>Aleksandra Havelka</b>	<b>2024</b>	<b>2023</b>
Outstanding options 01.01	70 000	40 000
Options granted	20 000	30 000
Options forfeited	-	-
Options exercised	-	-
Options expired	-10 000	-
Outstanding options 31.12	80 000	70 000

<b>Markus Jaquemar</b>	<b>2024</b>	<b>2023</b>
Outstanding options 01.01	87 500	47 500
Options granted	40 000	40 000
Options forfeited	-	-
Options exercised	-	-
Options expired	-	-
Outstanding options 31.12	127 500	87 500

  

<b>Frank Frantzen</b>	<b>2024</b>	<b>2023</b>
Outstanding options 01.01	-	-
Options granted	50 000	-
Options forfeited	-	-
Options exercised	-	-
Options expired	-	-
Outstanding options 31.12	50 000	-

For options issued in 2020 - 2021, the vesting period is over three years as follows:

- 1/3 of the options granted no earlier than 2 years after allocation
- 1/3 of the options granted no earlier than 3 years after allocation
- 1/3 of the options granted no earlier than 4 years after allocation

For options issued in 2022-2024, the vesting period is over two years as follows:

- 1/2 of the options granted no earlier than 3 years after allocation
- 1/2 of the options granted no earlier than 4 years after allocation

All outstanding options will immediately vest if a single shareholder acquires more than 50% of the company's shares. In addition, any acquisition, sale, or disposition of shares or assets of the Company, or any merger or other form of consolidation resulting in a change of ownership of all or substantially all of the Company's assets, will also lead to immediate vesting of all outstanding options.

The options expire five years after issuance.

**Table - 9**

<b>2024</b>								
<b>Expiry date</b>	<b>Average strike price</b>	<b>Number of share options</b>	<b>Matti Heinonen</b>	<b>Hilja Ibert</b>	<b>Njaal Kind</b>	<b>Aleksandra Havelka</b>	<b>Markus Jaquemar</b>	<b>Frank Frantzen</b>
2025-11	62.88	100 000	-	-	40 000	-	20 000	-
2026-11	72.60	135 674	-	-	40 674	20 000	2 500	-
2027-11	46.67	209 996	-	80 000	19 996	10 000	25 000	-
2028-12	40.17	339 962	-	139 962	40 000	30 000	40 000	-
2029-11	50.39	295 000	100 000	-	40 000	20 000	40 000	50 000
		1 080 632	100 000	219 962	180 670	80 000	127 500	50 000

<b>2023</b>						
<b>Expiry date</b>	<b>Average strike price</b>	<b>Number of share options</b>	<b>Hilja Ibert</b>	<b>Njaal Kind</b>	<b>Aleksandra Havelka</b>	<b>Markus Jaquemar</b>
2024-11	47.51	259 962	139 962	40 000	10 000	-
2025-11	62.88	150 000	-	40 000	-	20 000
2026-11	72.60	155 674	-	40 674	20 000	2 500
2027-12	46.67	209 996	80 000	19 996	10 000	25 000
2028-11	40.17	339 962	139 962	40 000	30 000	40 000
		1 115 594	359 924	180 670	70 000	87 500

## 5. Use of right to reclaim

Not applicable in Gentian Diagnostics ASA.

## 6. Deviation from the remuneration policy.

Nothing to report.

## 7. Comparative information on change on remuneration.

Table - 10

Comparative information on change in remuneration						
Yearly Change	Δ 2024	Δ 2023	Δ 2022	Δ 2021	Δ 2020	Comment
Salary compensation						
CEO	-	-	-	-	-	
Former CEO	-	4.0 %	-12.6 %	-4.4 %	26.2 %	New CEO from 01.10.2024
Group CFO	10.3 %	-9.6 %	15.5 %	20.6 %	7.7 %	
CSO	27.8 %	-	-	-	-	New CSO from 01.01.2023
Former CSO	-	-	-1.0 %	25.9 %	28.4 %	
CCO	12.9 %	23.6 %	-	-	-	New position in 2022
CTO	-	-	-	-	-	New position in 2024
MCAP - end year (1000 NOK)	604 556	640 028	632 316	1 110 409	839 948	
Company EBIT (1000 NOK)	15 723	- 12 762	- 23 235	- 22 847	- 17 824	
Change in average compensation employees	-8 %	8 %	5 %	-2 %	20 %	
Total number of employees	63	58	55	52	47	

## 8. Information on shareholder vote

At the General meeting in 2024 the following items were voted on in relation to remuneration:

Item 7 – Advisory vote on remuneration report.

The presented guidelines were approved with the following votes:

For	Against	Abstain	Total
8 363 618 (81.5 %)	1 903 962 (18.5 %)	0 (0 %)	10 267 580 (100 %)

To the General Meeting of Gentian Diagnostics ASA

## **Independent auditor's assurance report on report on salary and other remuneration to directors**

### **Opinion**

We have performed an assurance engagement to obtain reasonable assurance that Gentian Diagnostics ASA's report on salary and other remuneration to directors (the remuneration report) for the financial year ended 31 December 2024 has been prepared in accordance with section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation.

In our opinion, the remuneration report has been prepared, in all material respects, in accordance with section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation.

### **Board of directors' responsibilities**

The board of directors is responsible for the preparation of the remuneration report and that it contains the information required in section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation and for such internal control as the board of directors determines is necessary for the preparation of a remuneration report that is free from material misstatements, whether due to fraud or error.

### **Our independence and quality control**

We are independent of the company as required by laws and regulations and the International Ethics Standards Board for Accountants' Code of International Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. The firm applies International Standard on Quality Management, which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

### **Auditor's responsibilities**

Our responsibility is to express an opinion on whether the remuneration report contains the information required in section 6-16 b of the Norwegian Public Limited Liability Companies Act and the accompanying regulation and that the information in the remuneration report is free from material misstatements. We conducted our work in accordance with the International Standard for Assurance Engagements (ISAE) 3000 – "Assurance engagements other than audits or reviews of historical financial information".



We obtained an understanding of the remuneration policy approved by the general meeting. Our procedures included obtaining an understanding of the internal control relevant to the preparation of the remuneration report in order to design procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. Further we performed procedures to ensure completeness and accuracy of the information provided in the remuneration report, including whether it contains the information required by the law and accompanying regulation. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Moss, 19 March 2025  
BDO AS

Per Harald Eskedal  
State Authorised Public Accountant  
(This document is signed electronically)

# PENNEO

Signaturene i dette dokumentet er juridisk bindende. Dokument signert med "Penneo™ - sikker digital signatur". De signerende parter sin identitet er registrert, og er listet nedenfor.

"Med min signatur bekrefter jeg alle datoer og innholdet i dette dokument."

## Eskedal, Per Harald

### Partner

På vegne av: BDO AS

Serienummer: no\_bankid:9578-5999-4-2409404

IP: 188.95.xxx.xxx

2025-03-19 16:39:51 UTC



Dette dokumentet er signert digitalt via **Penneo.com**. De signerte dataene er validert ved hjelp av den matematiske hashverdien av det originale dokumentet. All kryptografisk bevisføring er innebygd i denne PDF-en for fremtidig validering.

Dette dokumentet er forseglet med et kvalifisert elektronisk segl ved bruk av et sertifikat og et tidsstempel fra en kvalifisert tillitstjenesteleverandør.

### Slik kan du bekrefte at dokumentet er originalt

Når du åpner dokumentet i Adobe Reader, kan du se at det er sertifisert av **Penneo A/S**. Dette beviser at innholdet i dokumentet ikke har blitt endret siden tidspunktet for signeringen. Bevis for de individuelle signatørens digitale signaturer er vedlagt dokumentet.

Du kan bekrefte de kryptografiske bevisene ved hjelp av Penneos validator, <https://penneo.com/validator>, eller andre valideringsverktøy for digitale signaturer.